Oocyte maturation in rabbits: effects of calmodulin inhibitors.
Oocyte maturation in mammals follows a highly conserved pattern of release from arrest through to the extrusion of the first polar body and formation of the second metaphase spindle. Oscillations in cytoplasmic calcium concentration precede the events of maturation in many species. These calcium ions interact with and activate calcium-binding proteins, including calmodulin, within the cell. Thus, it was of interest to us to examine whether calcium acted through calmodulin in the initial stages of maturation in rabbit oocytes or whether calmodulin was required for continuation through metaphase I no to metaphase II. Using the calmodulin inhibitor W-7 we found a significant (p < 0.05) decrease in the percentage of oocytes that underwent germinal vesicle breakdown. Calmidazolium did not prevent germinal vesicle breakdown; however, it caused a significant (p < 0.05) decrease in the proportion of oocytes with fully elaborated spindles and taxol-induced cytoplasmic asters. Both inhibitors caused a significant (p < 0.05) reduction in the proportion of oocytes that extruded their first polar bodies. The kinase inhibitor 6-DMAP caused a significant reduction in the proportion of oocytes with spindles and condensed chromatin, indicating the necessity for phosphorylation events in the resumption of meiosis. In rabbit oocytes calmodulin may play a role in the release from prophase arrest, and it is necessary for spindle preservation and continuation through metaphase I to metaphase II. The varying effects of the two inhibitor stems from their different binding sites on the calmodulin molecule thus causing a differential effect on its downstream effectors.
Henry
M A
MA
Department of OB/GYN, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA.
Rawlins
R G
RG
Radwanska
E
E
Fahy
M M
MM
D000225:Adenine / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000818:Animals; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D002147:Calmodulin / Q000037:antagonists & inhibitors / Q000502:physiology*; D002843:Chromatin / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D007093:Imidazoles / Q000494:pharmacology*; D007150:Immunohistochemistry; D008856:Microscopy, Fluorescence; D009865:Oocytes / Q000187:drug effects / Q000254:growth & development* / Q000502:physiology; D017239:Paclitaxel / Q000494:pharmacology; D047428:Protein Kinase Inhibitors; D011817:Rabbits; D008941:Spindle Apparatus / Q000502:physiology; D013449:Sulfonamides / Q000494:pharmacology*
D002147:Calmodulin; D002843:Chromatin; D004791:Enzyme Inhibitors; D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; C031938:calmidazolium; C001020:N(6),N(6)-dimethyladenine; C017967:W 7; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D000225:Adenine; D017239:Paclitaxel